MEZVURXO

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Jun 2024 filing date already counts against anyone who files later.

Record

Serial number

98595264

Mark type

Stylized text

Filed

11 Jun 2024

Published for opposition

14 Oct 2025

Attorney of record

Xiomara Triana

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; anticoagulants for human use; pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; pharmaceutical and biological preparations for human use for immunotherapy, namely T-cell therapy preparations for the treatment of cancer; pharmaceutical and biological preparations for human use, namely, stem cells for medical use; pharmaceutical preparations for human use for the treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; pharmaceutical preparations for human use for the treatment of cystic fibrosis

Owner

• Celgene Corporation, Princeton, NJ, US
• Celgene Corporation, Princeton, NJ, US

Prosecution history

• 09 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 14 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 14 Oct 2025 — PUBLISHED FOR OPPOSITION
• 08 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 13 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 13 Aug 2025 — EXAMINER'S AMENDMENT ENTERED
• 13 Aug 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 13 Aug 2025 — EXAMINERS AMENDMENT E-MAILED
• 13 Aug 2025 — EXAMINERS AMENDMENT -WRITTEN
• 12 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 12 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 12 Aug 2025 — ASSIGNED TO LIE
• 05 Aug 2025 — NOTICE OF REVIVAL - E-MAILED
• 05 Aug 2025 — PETITION GRANTED - RESPONSE RECEIVED
• 04 Aug 2025 — ASSIGNED TO PETITION STAFF